201 related articles for article (PubMed ID: 33483615)
21. Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.
García-Ramírez I; Bhatia S; Rodríguez-Hernández G; González-Herrero I; Walter C; González de Tena-Dávila S; Parvin S; Haas O; Woessmann W; Stanulla M; Schrappe M; Dugas M; Natkunam Y; Orfao A; Domínguez V; Pintado B; Blanco O; Alonso-López D; De Las Rivas J; Martín-Lorenzo A; Jiménez R; García Criado FJ; García Cenador MB; Lossos IS; Vicente-Dueñas C; Borkhardt A; Hauer J; Sánchez-García I
EMBO J; 2018 Jul; 37(14):. PubMed ID: 29880602
[TBL] [Abstract][Full Text] [Related]
22. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.
Latchmansingh KA; Wang X; Verdun RE; Marques-Piubelli ML; Vega F; You MJ; Chapman J; Lossos IS
Mod Pathol; 2022 Sep; 35(9):1220-1226. PubMed ID: 35322192
[TBL] [Abstract][Full Text] [Related]
23. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
24. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.
Van Vlierberghe P; van Grotel M; Beverloo HB; Lee C; Helgason T; Buijs-Gladdines J; Passier M; van Wering ER; Veerman AJ; Kamps WA; Meijerink JP; Pieters R
Blood; 2006 Nov; 108(10):3520-9. PubMed ID: 16873670
[TBL] [Abstract][Full Text] [Related]
25. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia.
Ferrando AA; Herblot S; Palomero T; Hansen M; Hoang T; Fox EA; Look AT
Blood; 2004 Mar; 103(5):1909-11. PubMed ID: 14604958
[TBL] [Abstract][Full Text] [Related]
26. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
[TBL] [Abstract][Full Text] [Related]
27. Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.
Deleuze V; El-Hajj R; Chalhoub E; Dohet C; Pinet V; Couttet P; Mathieu D
PLoS One; 2012; 7(7):e40484. PubMed ID: 22792348
[TBL] [Abstract][Full Text] [Related]
28. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.
El Omari K; Hoosdally SJ; Tuladhar K; Karia D; Vyas P; Patient R; Porcher C; Mancini EJ
Blood; 2011 Feb; 117(7):2146-56. PubMed ID: 21076045
[TBL] [Abstract][Full Text] [Related]
29. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
[TBL] [Abstract][Full Text] [Related]
30. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
[TBL] [Abstract][Full Text] [Related]
31. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
[TBL] [Abstract][Full Text] [Related]
32. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic utility of LMO2 immunohistochemistry in distinguishing T-lymphoblastic leukemia/lymphoma from thymoma.
Bansal D; Pasricha S; Gupta G; Sharma A; Durga G; Kamboj M; Mehta A
Indian J Pathol Microbiol; 2024; 67(1):141-144. PubMed ID: 38358204
[TBL] [Abstract][Full Text] [Related]
34. Cooperation between somatic Ikaros and Notch1 mutations at the inception of T-ALL.
Sontani Y; Chapman G; Papathanasiou P; Dunwoodie S; Goodnow CC; Hoyne GF
Leuk Res; 2011 Nov; 35(11):1512-9. PubMed ID: 21840596
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous rearrangements of TAL1 and LMO2 in T-cell acute lymphoblastic leukemia.
Kim HK; Lim JH; Koh KN; Chi HS; Seo EJ
Int J Lab Hematol; 2014 Oct; 36(5):e69-70. PubMed ID: 24330618
[No Abstract] [Full Text] [Related]
36. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
37. Of mice and men: how an oncogene transgresses the limits and predisposes to T cell acute lymphoblastic leukemia.
Hoang T
Sci Transl Med; 2010 Mar; 2(21):21ps10. PubMed ID: 20374994
[TBL] [Abstract][Full Text] [Related]
38. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.
Jevremovic D; Roden AC; Ketterling RP; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2016 Feb; 145(2):180-90. PubMed ID: 26796495
[TBL] [Abstract][Full Text] [Related]
39. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.
McCormack MP; Forster A; Drynan L; Pannell R; Rabbitts TH
Mol Cell Biol; 2003 Dec; 23(24):9003-13. PubMed ID: 14645513
[TBL] [Abstract][Full Text] [Related]
40. Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1
Schjerven H; Ayongaba EF; Aghajanirefah A; McLaughlin J; Cheng D; Geng H; Boyd JR; Eggesbø LM; Lindeman I; Heath JL; Park E; Witte ON; Smale ST; Frietze S; Müschen M
J Exp Med; 2017 Mar; 214(3):793-814. PubMed ID: 28190001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
